Clinical trials have revealed the Alzheimer’s drug donanemab slows the progression of the disease  by 35%.

Re:Cognition Health, a pioneering brain and mind clinic specialising in the delivery of clinical trials, said it was thrilled to have taken part in the TRAILBLAZER-ALZ 2 study.

Dr Emer MacSweeney, chief executive and medical director at Re:Cognition Health and principal investigator for the TRAILBLAZER-ALZ 2, said: “Re:Cognition Health is honoured to be involved in the clinical investigation of donanemab, which represents a significant advancement in the pursuit of effective Alzheimer’s treatments. We recognise the urgent need for new and innovative therapies to combat Alzheimer’s disease, and we are excited to contribute to the development of this potentially groundbreaking treatment.

“The results of TRAILBLAZER-ALZ 2 are hugely exciting and we are proud to be offering patients the opportunity to access more opportunities in clinical trials. With every study conducted, we are helping more people and taking greater steps to find a cure and potentially change the course of the disease for thousands of individuals affected by Alzheimer’s.”

The trial included 1,736 international participants, 62 from the UK who all participated through Re:Cognition Health’s UK centres in London, Guildford and Birmingham.